

Polymorphisms and Coronary Disease

Lipoprotein Lipase Gene Polymorphisms and the Risk of Target Vessel Revascularization After Percutaneous Coronary Intervention

Pascal S. Monraats, MSc,*† Jamal S. Rana, MD,‡ Melchior C. Nierman, MD,‡ Nuno M. M. Pires, MSc,*§ Aeilko H. Zwinderman, PhD,|| John J. P. Kastelein, MD, PhD,‡ Jan Albert Kuivenhoven, PhD,‡ Moniek P. M. de Maat, PhD,¶|| Saskia Z. H. Rittersma, MD# Abbey Schepers, MD,§** Pieter A. F. Doevendans, MD, PhD,†† Robbert J. de Winter, MD, PhD,# René A. Tio, MD, PhD,‡‡ Rune R. Frants, PhD,§§ Paul H. A. Quax, PhD,§** Arnoud van Der Laarse, PhD,* Ernst E. van Der Wall, MD, PhD,* J. Wouter Jukema, MD, PhD*† *Leiden, Utrecht, Amsterdam, Rotterdam, and Groningen, the Netherlands*

OBJECTIVES	We sought to identify polymorphisms in genes that predispose to restenosis.
BACKGROUND	Variations in the lipoprotein lipase (LPL) gene have been implicated in a number of pathophysiologic conditions associated with coronary heart disease. The present study examines the impact of polymorphisms in the LPL gene on restenosis (defined by target vessel revascularization [TVR]) in a large patient population undergoing percutaneous coronary intervention (PCI). A mouse model for restenosis was used to further investigate LPL's role in restenosis.
METHODS	The GENetic DEterminants of Restenosis (GENDER) project is a multicenter, prospective study design that enrolled 3,104 consecutive patients after successful PCI. These patients were genotyped for four different LPL gene polymorphisms. In apolipoprotein E (ApoE)*3-Leiden transgenic mice, arterial messenger ribonucleic acid (mRNA) was used to assess LPL expression during a cuff-induced restenotic process.
RESULTS	Using multivariable analysis, carriers of the 447Ter allele of the LPL enzyme showed a lower risk of TVR compared with 447Ser homozygotes ($p = 0.005$). In the mouse model, LPL mRNA levels were increased 40-fold compared with control arteries at 6 h after cuff placement.
CONCLUSIONS	The LPL C/G polymorphism (Ser447Ter), resulting in a truncation of the two C-terminal amino acids of the mature LPL protein, appears to be an important protective factor for TVR in humans. The role of LPL in this process was further established in a mouse model, where LPL expression was very strongly up-regulated in the target arterial wall, suggesting a contribution of this lipolytic enzyme to restenosis. Possibly, LPL Ser447Ter genotyping may lead to better risk stratification and tailored therapy in the prevention of restenosis after PCI. (J Am Coll Cardiol 2005;46:1093-100) © 2005 by the American College of Cardiology Foundation

Lipoprotein lipase (LPL) is the rate-limiting enzyme in the lipolysis of plasma triglyceride-rich lipoproteins in the circulation. In adulthood, it is synthesized in parenchymal cells of adipose tissue, as well as in skeletal and cardiac muscle, followed by transfer to heparin sulfate-binding sites at the vascular side of the endothelium (1). The hydrolytic function of LPL is essential for the processing of triglyceride-rich chylomicrons and very-low-density lipoproteins (VLDLs) to rem-

nant particles and also for the transfer of phospholipids and apolipoproteins to high-density lipoprotein (HDL). Furthermore, LPL plays a key role in the receptor-mediated removal of lipoproteins from the circulation (2). The gene coding for LPL, located on chromosome 8p22, encompasses 10 exons and is rather polymorphic (3). Abnormal LPL function has been reported to be associated with a number of pathophysiologic conditions that underlie coronary heart disease (4,5). In

From the *Department of Cardiology, Leiden University Medical Center, Leiden; †Interuniversity Cardiology Institute of the Netherlands (ICIN), Utrecht; ‡Department of Vascular Medicine, Academic Medical Center, Amsterdam; §Gaubius Laboratory, TNO-Quality of Life, Leiden; ||Department of Medical Statistics, Academic Medical Center, Amsterdam; ¶Department of Hematology, Erasmus University Medical Center, Rotterdam; #Department of Cardiology, Academic Medical Center, Amsterdam; **Department of Surgery, Leiden University Medical Center, Leiden; ††Department of Cardiology, University Medical Center, Utrecht; ‡‡Department of Cardiology, Academic Hospital, Groningen; and the §§Department of Human Genetics, Center for Human and Clinical Genetics, Leiden

University Medical Center, Leiden, the Netherlands. The study sponsor had no role in the design or conduct of the study, the writing of this report, or the decision to submit it for publication. Dr. Monraats is supported by grant 99.210 from the Netherlands Heart Foundation and a grant from the Interuniversity Cardiology Institute of the Netherlands (ICIN). Dr. Quax (Established Investigator) and Dr. Schepers are supported by the Molecular Cardiology Program of the Netherlands Heart Foundation (M 93.001). Dr. Jukema is an Established Clinical Investigator of the Netherlands Heart Foundation (2001 D 032).

Manuscript received April 25, 2005; revised manuscript received May 20, 2005, accepted May 24, 2005.

Abbreviations and Acronyms

CABG	= coronary artery bypass graft surgery
HDL	= high-density lipoprotein
LDL	= low-density lipoprotein
LPL	= lipoprotein lipase
NO	= nitric oxide
PCI	= percutaneous coronary intervention
PCR	= polymerase chain reaction
TVR	= target vessel revascularization
VLDL	= very-low-density lipoprotein

line, changes in LPL gene expression, or amino acid substitutions as a result of point mutation in the LPL gene, affect triglyceride and HDL cholesterol levels, which in turn are implicated in atherosclerotic risk (6,7).

Percutaneous coronary intervention (PCI), an important treatment for patients with atherosclerosis, is limited by the development of restenosis, despite the advent of drug-eluting stents. There is increasing evidence that inherited factors may partly explain the excessive risk of restenosis in certain patients. Identifying such patients may improve stratification of patients to a more individually tailored treatment (8,9).

To our knowledge, the role of LPL polymorphisms in restenosis has thus far not been investigated. Therefore, the purpose of the current study was to evaluate in a large consecutive study population whether four different well-known variants in the LPL gene, denoted as -93T/G, Asp9Asn, Asn291Ser, and Ser447Ter, have predictive value toward the risk of restenosis (defined by target vessel revascularization [TVR]) after PCI. To further establish the role of LPL in restenosis, we quantified LPL messenger ribonucleic acid (mRNA) expression in the restenotic vessel in an established mouse model for restenosis (10-12).

METHODS

Study design. The present study population has been described previously (13). In brief, the GENetic DEterminants of Restenosis (GENDER) project was designed to study the association between genetic polymorphisms and clinical restenosis. Patients were eligible for inclusion if they were successfully treated for stable angina, non-ST-segment elevation acute coronary syndromes, or silent ischemia by PCI. Patients treated for acute ST-segment elevation myocardial infarction were excluded. All patients were treated in 4 of the 13 referral centers for interventional cardiology in the Netherlands. The overall inclusion period lasted from March 1999 until June 2001.

The study protocol conforms to the Declaration of Helsinki and was approved by the Medical Ethics Committee of each participating institution. Written, informed consent was obtained from each participant before the PCI procedure.

The PCI procedure. Standard angioplasty and stent placement were performed by experienced operators using a

radial or femoral approach. Before the procedure, patients received 300 mg aspirin and 7,500 IU heparin. The use of intracoronary stents and additional medication, such as glycoprotein IIb/IIIa inhibitors, was at the discretion of the operator. In case of stent implantation, patients received either ticlopidine or clopidogrel for at least one month after the procedure, depending on local practice. During the study, no drug-eluting stents were used.

Follow-up and study end points. Follow-up lasted at least nine months, except when a coronary event occurred. Patients were either seen in the outpatient clinic or contacted by telephone. Target vessel revascularization, either by PCI or coronary artery bypass graft surgery (CABG), was considered as restenosis and was our primary end point. An independent Clinical Events Committee adjudicated the clinical events.

Events occurring within the first month were excluded from the analysis, as these events were attributable mainly to subacute stent thrombosis or occluding dissections, and less likely to restenosis. Data were collected with standardized case-report forms that were completed by the research coordinator at each site, who was blinded to the genotype of the patients. Representatives from the data-coordinating center monitored all sites.

Genotyping. Blood was collected in EDTA tubes at baseline, and DNA was extracted after standard procedures. The LPL G/A, A/G, and C/G polymorphisms in exons 2, 6, and 9, respectively, resulting in the following amino acid substitutions—Asp9Asn, Asn291Ser, and Ser447Ter, respectively—were determined by validated multilocus genotyping assay (Roche Molecular Systems, Alameda, California) (14). A similar method was used to detect the LPL -93T/G promoter polymorphism. All four polymorphisms were selected on the basis of their previously described relation to coronary artery disease and/or their influence on LPL activity (14,15). In short, each DNA sample was amplified in a multiple polymerase chain reaction (PCR) using biotinylated primers. The PCR product pool was then hybridized to a matching panel of sequence-specific oligonucleotide probes immobilized in a linear array on nylon membrane strips. A colorimetric detection method based on incubation with streptavidin-horseradish peroxidase conjugate, using hydrogen peroxide and 3,3',5,5'-tetramethylbenzidine as substrates, was used. Operators blinded to restenosis status performed genotyping.

To confirm genotype assignments, the PCR procedure was performed in replicate on 10% of the samples. Two independent observers carried out scoring. Disagreements (<1%) were resolved by further joint reading, and when necessary, genotyping was repeated.

Lipid analysis. To study the effect of the different LPL variants on lipid levels, we measured plasma triglycerides, total cholesterol, and HDL cholesterol in a subpopulation of patients. Cholesterol and triglyceride concentrations in serum were measured with a fully automated Hitachi 747 (Hitachi, Tokyo, Japan). The HDL cholesterol level was determined by a turbidimetric assay on a Hitachi 911.

Low-density lipoprotein cholesterol was calculated according to the equation of Friedewald et al. (16). Blood was drawn before the PCI procedure. Two of the four participating centers (Leiden University Medical Center and Academic Hospital Maastricht) systematically collected extra blood samples to perform additional laboratory measurements to examine other predictors of restenosis.

Mouse model of restenosis. We further studied LPL gene expression during the development of restenosis in an established mouse model for diet-induced atherosclerosis. Specifically, we analyzed LPL mRNA levels in the vessel wall of apolipoprotein E (ApoE)*3-Leiden transgenic mice after cuff placement (10–12). Before cuff placement, the mice were fed a Western-type diet containing 1% cholesterol and 0.05% cholate (Hope Farms, Woerden, the Netherlands) three weeks before surgery and continued after surgery in order to obtain stable plasma cholesterol levels. This diet results in a human-like lipoprotein profile (10). Femoral arteries, either cuffed or non-cuffed sham-operated, were pooled (two arteries per sample, two samples per time point), and total RNA was isolated per time point using the Trizol protocol (Invitrogen, Breda, the Netherlands). Subsequently, cDNA synthesis of all RNA samples was achieved using Ready-To-Go real-time (RT)-PCR beads (Amersham Biosciences, Uppsala, Sweden). All experimental procedures in mice were approved by the Animal Welfare Committee of TNO-PG, Leiden, the Netherlands.

Intron-spanning primers (forward: 5'GTGGCCGAG-AGCGAGAAC-3', reverse: 5'TCCACCTCCGTGTAA-ATCAAGA-3') and probe (5'TTCCCTTCACCCTGCCGAGGTT-3') for mouse LPL gene were designed using Primer Express 1.5 software (Perkin-Elmer Applied Biosystems, Foster City, California). The housekeeping genes—hypoxanthine-guanine phosphoribosyl transferase, cyclophilin, and GAPDH—were used as controls. Real-time PCR was performed on an ABI Prism 7700 sequence detection system (Perkin Elmer Biosystems, Boston, Massachusetts). Cycle conditions were: 50°C for 2 min, followed by 10 min at 95°C, amplification phase of 45 cycles of 15 s at 95°C, followed by 1 min at 60°C. The RT-PCR analysis was performed using RT-PCR mastermix (Eurogentec, Seraing, Belgium). Aqua-dest was incorporated as a negative control.

Statistical methodology. Deviations of the genotype distribution from that expected for a population in Hardy-Weinberg equilibrium was tested using the chi-square test with one degree of freedom. Allele frequencies were determined by counting; the 95% confidence intervals of the allele frequencies were calculated from sample allele frequencies, based on the approximation of the binomial and normal distributions in large sample sizes. Polymorphisms not in Hardy-Weinberg equilibrium were excluded from further analysis.

In the first stage, the association between each LPL polymorphism and TVR was assessed using a Cox proportional regression model under a co-dominant genetic model.

No adjustment for co-variables was performed at this stage to allow for the assessment of their possible involvement in the causal pathway. If <10 patients were homozygous for a particular allele, two groups were formed with the absence or presence of that allele as group variable.

All polymorphisms were also assessed using dominant and recessive models, and the model with the lowest Akaike information criterion was used in multivariable regression analysis (17). The LPL polymorphisms were combined into haplotypes, and the effect of haplotypes on restenosis risk was estimated according to the methods developed by Tanck et al. (18).

Multivariable regression analysis of TVR risk was performed on all polymorphisms using a stepwise backward selection algorithm. In the final step, clinical variables associated with TVR or associated with genotype were entered into the regression model. The Kruskal-Wallis test was used to examine the association of the different genotypes with concentrations of HDL cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride levels.

Animal data are presented as the mean value \pm SEM. Data were analyzed using the Mann-Whitney *U* test. A *p* value <0.05 was considered statistically significant. Statistical analysis was carried out using SPSS version 11.5.

RESULTS

Patient characteristics. A total of 3,146 patients had complete follow-up (99.3%), with a median duration of 9.6 months (interquartile range 3.9). A total number of 42 patients experienced an event in the first 30 days and were therefore excluded from further analysis, according to the protocol. In the remaining 3,104 patients, we assessed the frequencies of the following LPL polymorphisms; –93T/G, Asp9Asn (G/A), Asn291Ser (A/G), and Ser447Ter (C/G). Successful DNA genotyping was possible in 3,028, 3,031, 3,021, and 3,054 patients, respectively. The results of the remaining patients were missing due to a lack of DNA or inconclusive genotyping. The frequencies of the rare –93G, 9Asn, 291Ser, and 447Ter alleles were 0.02, 0.02, 0.03, and 0.10, respectively.

The genotype distributions were consistent with Hardy-Weinberg equilibrium (*p* > 0.05), except for the –93T/G polymorphism. Therefore, this promoter polymorphism was excluded from further analysis.

Comparisons of baseline characteristics among the genotypes are shown in Table 1. The low frequency of carriers of 9Asn and 291Ser has prompted us to pool heterozygotes and homozygotes for these two LPL variants. No statistically significant differences were observed between the groups, with the following two exceptions: heterozygotes and homozygotes for the allele encoding for a 291Ser genotype had a higher rate of previous CABG (*p* < 0.05). Furthermore, heterozygotes and homozygotes for the allele encoding for the 9Asn LPL variant used less lipid-lowering medication but had a higher use of beta-blocker medication. Lesion-related and procedural parameters of the genotype

Table 1. Baseline Clinical Characteristics of Patients According to the Genotypes of LPL Polymorphisms

	LPL G/A (Asp9Asn)		LPL A/G (Asn291Ser)		LPL C/G (Ser447Ter)		
	GG (n = 2,933)	GA/AA (n = 98)	AA (n = 2,866)	AG/GG (n = 155)	CC (n = 2,452)	CG (n = 571)	GG (n = 31)
Age (yrs)	62 ± 10.7	62 ± 10.8	62 ± 10.7	62 ± 11.0	62 ± 10.7	62 ± 10.6	62 ± 11.2
Male	71.3	72.4	71.3	72.9	71.4	71.6	74.2
Hypertension	40.7	33.7	40.3	43.2	41.1	38.2	32.3
Hypercholesterolemia	60.7	67.3	60.7	65.8	61.8	56.9	61.3
Diabetes	14.5	15.3	14.5	14.8	14.8	14.0	3.2
Current smoker	24.5	21.4	24.6	20.6	25.2	21.4	25.8
Family history of MI	35.3	34.7	35.4	33.5	34.8	37.3	35.5
Previous MI	39.9	34.7	39.7	41.3	39.8	39.9	38.7
Previous CABG	12.3	8.2	12.1	14.2*	11.9	13.5	9.7
Lipid-lowering medication	54.0	65.3*	54.4	53.5	55.1	51.5	45.2
Beta-blocker medication	79.0	65.3*	78.7	75.5	78.8	77.8	71.0

*p < 0.05 in comparison with the other genotypes; p = not significant for all other comparisons. Age is expressed as the mean value ± SD; other variables are expressed as percentage of patients.

Asn = asparagine; Asp = aspartic acid; CABG = coronary artery bypass graft surgery; LPL = lipoprotein lipase; MI = myocardial infarction; Ser = serine; Ter = stop.

groups are presented in Table 2. The only significant difference was found for carriers of the allele encoding for 9Asn, who were treated more often for total occlusion, compared with homozygotes for the common allele (p < 0.05). Interestingly, homozygotes for the 447Ter genotype presented with a high statistically significant reduction in multivessel disease compared with the other genotypes (p = 0.002). In fact, we observed a gene dosage effect emphasizing a relationship between these two parameters.

At follow-up, 304 patients (9.8%) had to undergo TVR. We did observe a significant association between the 447Ter genotype and the rates of TVR after univariate analysis (relative risk [RR] 0.6, 95% confidence interval [CI] 0.44 to 0.83; p = 0.004). In contrast, the LPL Asp9Asn, Asn291Ser variants did not show a significant association with TVR (p > 0.1) (Table 3).

The LPL 447Ter genotype remained associated with a decreased risk of TVR (RR 0.6, 95% CI 0.44 to 0.86) on multivariable analysis, including all three polymorphisms. Finally, in the regression model, we included patient and intervention-related characteristics that were previously described as related to TVR risk or genotype (such as age,

gender, diabetes, stenting, residual stenosis >20%, current smoking, total occlusion, lipid-lowering medication, beta-blocker use, multivessel disease, and previous CABG) (13). This backward stepwise selection yielded similar results (RR 0.6, 95% CI 0.44 to 0.86) (Table 4).

Furthermore, because the severity of stenosis before angioplasty as well as (especially) the severity of stenosis immediately after angioplasty are key determinants of the risk of restenosis, we have examined the effect of pre- and post-procedural lesion diameter for the different genotypes in a subpopulation of 478 patients with additional angiographic data. However, pre- and post-percent stenosis values did not differ significantly between the three genotypes of the 447 polymorphism (p = 0.75 and p = 0.83, respectively).

The polymorphisms were also combined into haplotypes for further analysis. Seven of eight possible haplotypes were observed (data not shown). The 9G/291A/447C haplotype was most common in both TVR cases and controls (89.7% and 85.1%, respectively). A smallest RR was seen with respect to the 9G/291A/447G haplotype (RR 0.62, 95% CI 0.45 to 0.85). When evaluating bilocus haplotypes, it

Table 2. Lesion and Procedural Characteristics at the Time of Intervention According to the Genotypes of the LPL Polymorphisms

	LPL G/A (Asp9Asn)		LPL A/G (Asn291Ser)		LPL C/G (Ser447Ter)		
	GG (n = 2,933)	GA/AA (n = 98)	AA (n = 2,866)	AG/GG (n = 155)	CC (n = 2,452)	CG (n = 571)	GG (n = 31)
Restenotic lesion	6.8	5.1	6.8	5.8	7.1	5.6	3.2
Total occlusion	13.6	21.4*	13.7	14.2	13.9	13.8	6.5
Type C lesion	25.5	32.7	25.7	25.2	26.1	24.5	12.9
Proximal LAD	22.3	18.4	22.0	24.5	22.3	21.9	25.8
RCx	26.9	30.6	27.1	26.5	27.2	26.8	12.9
Multivessel disease	46.2	48.0	46.3	45.5	47.6	42.0	22.6*
Stable angina	33.1	28.6	33.1	31.6	32.5	34.9	38.7
Residual stenosis >20%	11.6	10.2	11.7	9.2	11.3	12.2	3.2
Stenting	74.5	72.4	74.6	71.6	74.5	75.1	67.7
Glycoprotein IIb/IIIa antagonist	26.4	25.5	26.3	28.4	26.5	25.9	22.6

*p < 0.05 in comparison with the other genotypes of the same polymorphism; p = not significant for all other comparisons. Variables are expressed as percentage of patients.

LAD = left anterior descending coronary artery; RCx = circumflex branch of the left coronary artery; type C lesion = according to American College of Cardiology and American Heart Association; other abbreviations as in Table 1.

Table 3. Univariate Analysis of LPL Polymorphisms in Association With TVR and the Distributions of Polymorphisms

Polymorphisms	No. of Patients	TVR (%)	Model Used	P Value
Asp9Asn	3,031		Dominant	0.77
GG		9.7		
GA/AA		10.4		
Asn291Ser	3,021		Dominant	0.62
AA		9.9		
AG/GG		8.5		
Ser447Ter	3,054		Dominant	0.004
CC		10.5		
CG		7.0		
GG		0		

TVR = target vessel revascularization; other abbreviations as in Table 1.

became evident that this effect was caused only by the LPL 447 variant.

Lipid profiles were investigated in a subgroup of patients (n = 942, data not shown). We were not able to find a significant correlation between carriers and non-carriers of the polymorphisms investigated with regard to HDL cholesterol, LDL cholesterol, and triglycerides (p > 0.20). Correction of lipid levels in this subgroup analysis had no influence on the association of the different polymorphisms and TVR.

Subsequently, we evaluated if LPL gene expression played a role in the development of restenosis by analyzing arterial mRNA in an established model of restenosis in hypercholesterolemic mice. At the time of surgery, the total plasma cholesterol level was 13.9 ± 3.6 mmol/l.

The mRNA encoding LPL, isolated from the cuffed right femoral artery and untreated left femoral artery, was quantified at various time points after cuff placement (Fig. 1). The mRNA encoding LPL showed peak expression 6 h after cuff placement, where it showed a 40-fold increase compared with the normal artery. The LPL mRNA levels were back to baseline after 24 h of induction of the restenotic process. Sham-operated vessels (femoral artery prepared free, but without cuff placement) showed essentially the same results as non-operated vessels.

DISCUSSION

In a large, prospective, multicenter, follow-up study of consecutive patients, we demonstrated that the LPL

Table 4. Multivariable Cox Regression of Clinical Variables and LPL Ser447Ter Polymorphism Associated With TVR

	RR	95% CI		p Value
		Low	High	
Diabetes	1.52	1.14	2.01	0.004
Current smoker	0.73	0.54	0.97	0.03
Stenting	0.76	0.58	1.00	0.05
Total occlusion	1.51	1.12	2.02	0.006
Residual stenosis >20%	1.35	0.97	1.89	0.08
LPL 447Ter	0.62	0.44	0.86	0.005

CI = confidence interval; RR = relative risk; other abbreviations as in Table 1.




Figure 1. Messenger ribonucleic acid (mRNA) expression of lipoprotein lipase in a cuffed femoral artery (as compared with hypoxanthine-guanine phosphoribosyl transferase mRNA expression, cuff vs. normal artery).

Ser447Ter variant, present in ~20% of the general population, is associated with a decreased risk of TVR after PCI (3). This polymorphism has been shown in most but not all studies to modulate lipid levels, as well as LPL (2,4,19–25). In fact, it was shown that this polymorphism is associated with decreased triglycerides, increased HDL cholesterol, and a decreased risk of coronary artery disease (4,26,27). Furthermore, a recent meta-analysis confirmed that the Ser447Ter variant has an effect on the lipoprotein profile, by decreasing plasma triglycerides and increasing HDL cholesterol (4). The mechanism responsible for cardiovascular protection and beneficial lipid profile changes observed in this LPL variant is not entirely clear. The data suggest that this variant may be catalytically normal with normal stability, but may be present at higher concentrations in the circulation associated with a higher level of LPL activity (2,4,21,28,29).

We did not find any associations for the other two polymorphisms and TVR.

The Asp9Asn substitution at the N-terminal end is situated near a glycosylation site, which may influence overall catalytic activity, whereas the Asn291Ser substitution is located in a heparin-binding cluster and may thus affect the interaction between LPL and the cell wall glycosaminoglycans. Both these two amino acid substitutions are located in the N-domain and likely reduce enzyme activity and consequently increase triglyceride levels.

The Ser447Ter substitution is located in the C-domain and thus may cause increased binding affinity of the truncated LPL to receptors or may affect its subunit interaction, either facilitating or otherwise affecting the formation of dimers, which would explain the opposite effect of this substitution compared with the other two, possibly forming the basis of the observed association (4,7).

In our study, we did not find a significant association between the LPL447 polymorphism and HDL and LDL cholesterol and triglyceride levels (data not shown). This could be due to the use of lipid-lowering medications in many of our patients.

Haplotype analyses showed that the difference in TVR

rate between the various haplotypes was completely explained by the LPL 447 variant.

In addition to the well-known role of LPL in the hydrolysis of the triglycerides packaged in chylomicrons and VLDL, several other functions of the enzyme have recently been identified. In particular, it has been shown that LPL increases monocyte adherence via a mechanism that requires an interaction between the C-terminal domain of the LPL, heparin sulfate proteoglycans, and integrins (30–32). However, Zhang et al. (29) showed that the affinity of LPL Ser447Ter for heparin sulfate proteoglycans was not different from wild-type LPL. Because LPL is also expressed in smooth muscle cells in the arterial media (33), the LPL Ser447Ter polymorphism may affect the level of interaction between smooth muscle cells and the extracellular matrix. The former could result in less arterial stiffness (34), leading to more distensible arteries and thus lesser propensity for restenosis.

On a completely different note, the LPL protein may also influence vascular tone by affecting the synthesis or degradation of endothelium-derived relaxing factors such as nitric oxide (NO). Endothelium-dependent vascular relaxation is abnormal in the setting of atherosclerosis, associated with subnormal endothelial nitric oxide synthase (eNOS) activity, the key enzyme in basal endothelial cell NO production. Nitric oxide dilates coronary arteries and promotes blood flow by inhibiting smooth muscle contraction, platelet aggregation, and platelet adhesion to endothelial cells by a cyclic guanosine monophosphate-mediated mechanism (35,36). In fact, LPL has been reported to increase NOS production and consequential increased NO production in culture macrophages. Lipoprotein lipase may well have a similar function in vivo in both macrophages and endothelial cells and may therefore have an effect on vascular tone (1,37). Therefore, mutated levels of LPL, as observed with the Ser447Ter polymorphism, may be beneficial for endothelial function, an important contributor involved in restenosis (38).

In addition, Ziouzenkova et al. (39) found a link between LPL and peroxisome proliferator-activated receptor (PPAR) activation, suggesting that impaired LPL enzymatic activity might decrease endogenous PPAR- α activation and its subsequent downstream effects, including anti-inflammatory responses. Inflammation has been previously reported as a very important component of restenosis (40–42).

Clee et al. (43) found a decrease in blood pressure independent of the lower level of triglycerides in patients with the LPL Ser447Ter polymorphism. Another study also showed that the LPL Ser447Ter polymorphism was associated with lower systolic blood pressure and pulse pressure levels in women (34). Because inflammation (40–42) and elevated blood pressure (44) have been implicated in increased risk of restenosis, any positive effect of this polymorphism on arterial tone, inflammatory status, and ele-

vated blood pressure may ultimately translate into lesser risk for restenosis.

Because we hypothesize a potential interaction between LPL activity by genotype and inflammatory activity, we also investigated several inflammatory markers, which could be of influence on the development of restenosis and their effect on TVR. These markers examined are the fibrinogen level, the erythrocyte sedimentation rate, and C-reactive protein. These markers were determined in a subgroup of patients from the GENDER project (in 753 patients for fibrinogen, in 1,000 patients for the erythrocyte sedimentation rate, and in 888 patients for C-reactive protein, respectively). All three factors, determined before PCI, did not have a statistically significant effect on TVR ($p > 0.20$), nor did they influence the general results for the LPL polymorphisms.

We further studied LPL gene expression during the development of restenosis in an established mouse model for diet-induced atherosclerosis. In the mouse model of restenosis, LPL mRNA levels were increased 40-fold compared with control arteries at 6 h after cuff placement. This indicates that LPL may play an important role in the early stages of the restenotic process development.

Study limitations. In our study, we lack data on LPL concentration and LPL activity in plasma. However, we believe that plasma determinations have no added value, owing to a number of reasons. Circulating LPL protein levels were not assessed here, as basal (before PCI) plasma measurements of the gene product are not likely to reflect the genetically determined differences in reaction to a trauma such as PCI. Moreover, local differences in LPL sensitive reactions, such as those occurring in the vessel wall at the site of PCI, cannot be measured systemically, as it is not yet possible to measure gene products in the vessel wall locally in the early phase of treatment or in the following days.

Furthermore, we made use of an atherosclerotic mouse model to study the effect of LPL on restenosis; in this model, we were not able to test the LPL polymorphisms found in humans. However, we believe that this model contributes to a better understanding of the involvement of LPL in the process of restenosis.

Although the mice studies can be used for analysis, it should be realized that perivascular cuff placement results initially in adventitial injury, whereas in patients with PCI, it results in intimal injury. It is not certain to what extent these apparently different ways of vascular injury differ in their reaction regarding vascular activation and the resulting intimal hyperplasia.

In addition, genotyping of some patients was missing due to a lack of DNA or inconclusive genotyping, and mistakes could have been made in the genotyping. However, patients who could not be genotyped did not differ in any characteristic from those who could be genotyped. Furthermore, the PCR procedure was per-

formed in replicate on 10%, and there was a difference observed in <1% of the samples.

The -93T/G polymorphism was not in Hardy-Weinberg equilibrium; the observed numbers of patients were 2,914 for T/T, 109 for T/G, and 5 for G/G, as opposed to the expected number of patients: 2,910 for T/T, 117 for T/G, and 1 for G/G. This discrepancy could be explained by the fact that it is possible that this polymorphism is associated with one or more inclusion/exclusion criteria; however, we cannot confirm this with our data, as all participants fulfilled those criteria. The most important inclusion criterion was that all participants were scheduled for PCI, and obviously the classic risk factors of cardiovascular disease will be enriched in such a population. The -93T/G polymorphism is sometimes found to be especially associated with HDL2 cholesterol, and ApoA-I levels with lower levels in -93G/G carriers (45). Based on this assumption, one might expect more heterozygote or homozygote carriers, and the latter were indeed slightly more present than expected.

Drug-eluting stents are now more widely used. In our study, we do not have any data on these stents, as no drug-eluting stents were used for our study, which can be seen as a limitation of our study. However, genes involved in the process of restenosis after drug-eluting stents are probably different from the process of restenosis after bare-metal stent placement or plain balloon angioplasty. Therefore, new studies are needed to investigate genes involved in the process of restenosis after drug-eluting stents.

Finally, the polymorphism associated with TVR in our study may be in linkage disequilibrium with other polymorphisms in the gene or with other nearby genes that are actually responsible for the development of this condition.

Conclusions. We have demonstrated that LPL is significantly associated with TVR. The LPL C/G polymorphism, which results in a 447 Ser→Stop (X) mutation, appears to be an important independent protective factor in this. Furthermore, LPL mRNA was highly up-regulated in the first 6 h after vascular damage in a mouse model of restenosis. Determination of this genotype could contribute to better risk stratification and more tailored therapy for the individual patient to prevent TVR after PCI.

Acknowledgments

We thank S. Cheng, M. Grow, and their colleagues at Roche Molecular Systems (Alameda, California) for developing and providing their multilocus genotyping assays under a research collaboration. We also thank P. Schiffers from the University of Maastricht for assistance with the genotyping assay. The contribution of the members of the Clinical Event Committee—J. J. Schipperheyne, MD, PhD, J. W. Viersma, MD, PhD, D. Düren, MD, PhD, and J. Vainer, MD—is greatly acknowledged.

Reprint requests and correspondence: Dr. J. Wouter Jukema, Leiden University Medical Center, Department of Cardiology, C5-P, P.O. Box 9600, 2300 RC Leiden, the Netherlands. E-mail: J.W.Jukema@lumc.nl.

REFERENCES

1. Kastelein JJ, Jukema JW, Zwiderman AH, et al., the REGRESS Study Group. Lipoprotein lipase activity is associated with severity of angina pectoris. *Circulation* 2000;102:1629–33.
2. Groenemeijer BE, Hallman MD, Reymer PW, et al., the REGRESS Study Group. Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. *Circulation* 1997;95:2628–35.
3. Sing K, Ballantyne CM, Ferlic L, et al. Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events: the Lipoproteins and Coronary Atherosclerosis Study. *Atherosclerosis* 1999;144:435–42.
4. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease: a meta-analysis. *Circulation* 1999;99:2901–7.
5. Jukema JW, van Boven AJ, Groenemeijer B, et al., the REression GRowth Evaluation Statin Study (REGRESS) Study Group. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. *Circulation* 1996;94:1913–8.
6. Murthy V, Julien P, Gagne C. Molecular pathobiology of the human lipoprotein lipase gene. *Pharmacol Ther* 1996;70:101–35.
7. Ukkola O, Garenc C, Perusse L, et al. Genetic variation at the lipoprotein lipase locus and plasma lipoprotein and insulin levels in the Quebec Family Study. *Atherosclerosis* 2001;158:199–206.
8. Kastrati A, Schomig A, Elezi S, Schühlen H, Wilhelm M, Dirschinger J. Interlesion dependence of the risk for restenosis in patients with coronary stent placement in multiple lesions. *Circulation* 1998;97:2396–401.
9. Weintraub WS, Kosinski AS, Brown CL III, King SB III. Can restenosis after coronary angioplasty be predicted from clinical variables? *J Am Coll Cardiol* 1993;21:6–14.
10. Lardenoye JH, Delsing DJ, de Vries MR, et al. Accelerated atherosclerosis by placement of a perivascular cuff and a cholesterol-rich diet in ApoE*3Leiden transgenic mice. *Circ Res* 2000;87:248–53.
11. Moroi M, Zhang L, Yasuda T, et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. *J Clin Invest* 1998;101:1225–32.
12. Quax PH, Lamfers ML, Lardenoye JH, et al. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. *Circulation* 2001;103:562–9.
13. Agema WRP, Monraats PS, Zwiderman AH, et al. Current PTCA practice and clinical outcomes in the Netherlands: the real world in the pre-drug-eluting stent era. *Eur Heart J* 2004;25:1163–70.
14. Cheng S, Grow MA, Pallaud C, et al. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. *Genome Res* 1999;9:936–49.
15. Barcellos LF, Begovich AB, Reynolds RL, et al. Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis. *Ann Neurol* 2004;55:793–800.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18:499–502.
17. Li W, Nyholt DR. Marker selection by Akaike information criterion and Bayesian information criterion. *Genet Epidemiol* 2001;21 Suppl 1:S272–7.
18. Tanck MW, Klerkx AH, Jukema JW, De Knijff P, Kastelein JJ, Zwiderman AH. Estimation of multilocus haplotype effects using weighted penalised log-likelihood: analysis of five sequence variations at the cholesteryl ester transfer protein gene locus. *Ann Hum Genet* 2003;67:175–84.

19. Chen W, Srinivasan SR, Elkasabany A, Ellsworth DL, Boerwinkle E, Berenson GS. Influence of lipoprotein lipase serine 447 stop polymorphism on tracking of triglycerides and HDL cholesterol from childhood to adulthood and familial risk of coronary artery disease: the Bogalusa Heart Study. *Atherosclerosis* 2001;159:367-73.
20. Gagne SE, Larson MG, Pimstone SN, et al. A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study. *Clin Genet* 1999;55:450-4.
21. Humphries SE, Nicaud V, Margalef J, Tiret L, Talmud PJ. Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides: the European Atherosclerosis Research Study (EARS). *Arterioscler Thromb Vasc Biol* 1998;18:526-34.
22. Jemaa R, Fumeron F, Poirier O, et al. Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the Etude Cas Témoin sur l'Infarctus du Myocarde (ECTIM) study. *J Lipid Res* 1995;36:2141-6.
23. Kozaki K, Gotoda T, Kawamura M, et al. Mutational analysis of human lipoprotein lipase by carboxy-terminal truncation. *J Lipid Res* 1993;34:1765-72.
24. Mattu RK, Needham EW, Morgan R, et al. DNA variants at the LPL gene locus associate with angiographically defined severity of atherosclerosis and serum lipoprotein levels in a Welsh population. *Arterioscler Thromb Vasc Biol* 1994;14:1090-7.
25. van Bockxmeer FM, Liu Q, Mamotte C, Burke V, Taylor R. Lipoprotein lipase D9N, N291S and S447X polymorphisms: their influence on premature coronary heart disease and plasma lipids. *Atherosclerosis* 2001;157:123-9.
26. Kuivenhoven JA, Groenemeyer BE, Boer JM, et al. Ser447stop mutation in lipoprotein lipase is associated with elevated HDL cholesterol levels in normolipidemic males. *Arterioscler Thromb Vasc Biol* 1997;17:595-9.
27. Sawano M, Watanabe Y, Ohmura H, et al. Potentially protective effects of the Ser447-Ter mutation of the lipoprotein lipase gene against the development of coronary artery disease in Japanese subjects via a beneficial lipid profile. *Jpn Circ J* 2001;65:310-4.
28. Henderson HE, Kastelein JJ, Zwiderman AH, et al. Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins. *J Lipid Res* 1999;40:735-43.
29. Zhang H, Henderson H, Gagne SE, et al. Common sequence variants of lipoprotein lipase: standardized studies of in vitro expression and catalytic function. *Biochim Biophys Acta* 1996;1302:159-66.
30. Nielsen MS, Brejning J, Garcia R, et al. Segments in the C-terminal folding domain of lipoprotein lipase important for binding to the low density lipoprotein receptor-related protein and to heparin sulfate proteoglycans. *J Biol Chem* 1997;272:5821-7.
31. Mamputu JC, Desfaits AC, Renier G. Lipoprotein lipase enhances human monocyte adhesion to aortic endothelial cells. *J Lipid Res* 1997;38:1722-9.
32. Obunike JC, Paka S, Pillarisetti S, Goldberg IJ. Lipoprotein lipase can function as a monocyte adhesion protein. *Arterioscler Thromb Vasc Biol* 1997;17:1414-20.
33. Camps L, Reina M, Llobera M, Vilaro S, Olivecrona T. Lipoprotein lipase: cellular origin and functional distribution. *Am J Physiol* 1990;258:C673-81.
34. Sass C, Herbeth B, Siest G, Visvikis S. Lipoprotein lipase (C/G)447 polymorphism and blood pressure in the Stanislas Cohort. *J Hypertens* 2000;18:1775-81.
35. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. *N Engl J Med* 1993;329:2002-12.
36. Radomski MW, Salas E. Nitric oxide—biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. *Atherosclerosis* 1995;118 Suppl:S69-80.
37. Renier G, Lambert A. Lipoprotein lipase synergizes with interferon gamma to induce macrophage nitric oxide synthetase mRNA expression and nitric oxide production. *Arterioscler Thromb Vasc Biol* 1995;15:392-9.
38. Horlitz M, Sigwart U, Niebauer J. Fighting restenosis after coronary angioplasty: contemporary and future treatment options. *Int J Cardiol* 2002;83:199-205.
39. Ziouzenkova O, Perrey S, Asatryan L, et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. *Proc Natl Acad Sci U S A* 2003;100:2730-5.
40. Hojo Y, Ikeda U, Katsuki T, et al. Chemokine expression in coronary circulation after coronary angioplasty as a prognostic factor for restenosis. *Atherosclerosis* 2001;156:165-70.
41. Serrano CV Jr., Ramires JA, Venturinelli M, et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression: evidence of inflammatory responses in coronary angioplasty. *J Am Coll Cardiol* 1997;29:1276-83.
42. Welt FG, Rogers C. Inflammation and restenosis in the stent era. *Arterioscler Thromb Vasc Biol* 2002;22:1769-76.
43. Clee SM, Loubser O, Collins J, Kastelein JJ, Hayden MR. The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. *Clin Genet* 2001;60:293-300.
44. Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. *J Am Coll Cardiol* 2002;40:2082-9.
45. Ferencak G, Pasalic D, Grskovic B, et al. Lipoprotein lipase gene polymorphisms in Croatian patients with coronary artery disease. *Clin Chem Lab Med* 2003;414:541-6.